Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361815 | 0.81 | TSHR (0.47) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL17603410 | 0.75 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL1826781 | 0.75 | GAA (0.46) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL10375523 | 0.75 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL6832323 | 0.75 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL5451 | 0.75 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL30283197 | 0.75 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL536014 | 0.75 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL28020967 | 0.75 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD | |
| SCHEMBL10499090 | 0.75 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GAAMAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| EP-1317419-B1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | SEKI MASAHIKO | 2009-01-22 | — | — | US | disclosed |
| US-7439368-B2 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | ALDH1A1 687/4885SMN1; SMN2 3442/4885GAA 4880/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | ALDH1A1 950/4885SMN1; SMN2 3744/4885GAA 4857/4885 |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | F12, F3, F11 | ALDH1A1 690/4885SMN1; SMN2 3833/4885GAA 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.